Breaking Finance News

finnCap issued a report on Synairgen PLC (LON:SNG), upholding its stock price target at 137.00GBX today

Synairgen PLC (LON:SNG) had its target hold steady to 137.00GBX by finnCap in an issued report issued Wednesday October 12, 2016. The latest price target suggests a potential upside of 5.09% based on the company's most recent stock price close.

On 9/22/2016, N+1 Singer released a statement for Synairgen PLC (LON:SNG) bumped down the target price from 47.00GBX to 46.00GBX that suggested an upside of 0.31%.

Boasting a price of 22.50GBX, Synairgen PLC (LON:SNG) traded -35.26% lower on the day. With the last stock price close down -29.56% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Synairgen PLC has recorded a 50-day average of 33.73GBX and a two hundred day average of 31.25GBX. Volume of trade was up over the average, with 228,091 shares of SNG changing hands over the typical 43,579

Performance Chart

Synairgen PLC (LON:SNG)

With a total market value of 0 GBX, Synairgen PLC has with a one year low of 19.00GBX and a one year high of 38.00GBX .

A total of 2 equity analysts have released a ratings update on SNG. zero equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 87.00GBX.

Brief Synopsis About Synairgen PLC (LON:SNG)

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.